FDA PreCheck Initiative

A Game-Changer for Facility Design and Construction

The announcement of the United States Food and Drug Administration (FDA) PreCheck Initiative in August 2025 marked a meaningful shift in how pharmaceutical manufacturing facilities can be planned, designed, and brought into operation in the US. Rather than waiting until construction is complete with a product application then being submitted, the PreCheck programme encourages earlier engagement between regulators and manufacturers. This approach is particularly relevant for organisations investing in new facilities, whether driven by onshoring strategies, supply chain resilience, or the need to modernise ageing infrastructure.

For Australian manufacturers with export ambitions, the initiative encourages deliberate embedding of regulatory expectations into facility design from the outset. By engaging earlier with the FDA, organisations may reduce late-stage surprises, support smoother inspections, and accelerate access to the US.

What is the FDA PreCheck Initiative

FDA PreCheck is a voluntary pilot programme designed to strengthen the domestic pharmaceutical supply chain by streamlining the regulatory review of new manufacturing facilities. Announced on 7 August 2025, and launched on 1 February 2026, the programme was introduced in response to Executive Order 14293, which directed the FDA to reduce regulatory barriers and promote domestic production of critical medicines.

At its core, the FDA PreCheck seeks to shift regulatory engagement earlier in the facility lifecycle. Instead of regulatory scrutiny at occurring at application review or pre-approval inspection, PreCheck creates structured dialogue opportunities during facility design, construction, and readiness phases.

The programme applies to both drug and biological product manufacturing, focusing on new, greenfield facilities supplying active pharmaceutical ingredients (API) or finished dosage forms.

Two Phases of FDA PreCheck: Supporting Earlier Design Confidence

The FDA PreCheck Initiative is structured around two complementary phases, each intended to support predictability and alignment.

Phase 1: Facility Readiness

During the Facility Readiness Phase, selected participants who are developing new pharmaceutical manufacturing facilities that align with program prioritiesare encouraged to share detailed facility information with the FDA while designs are still being developed or constructed. This information may be submitted via a Type V Drug Master File, covering elements such as site layout, cleanroom concepts, utilities, pharmaceutical quality system maturity, and overall state of readiness.

This phase is particularly valuable from a facility design and construction perspective. Engaging with the regulator at this point may help design teams validate assumptions, confirm expectations around segregation, flows, and environmental controls, and avoid costly redesigns later in the project.

Eligibility Criteria

• New manufacturing facility
• Located in the United States
• Facility size vs market need thresholds
• Specific regulatory submission stipulations

Phase 2: Application Submission

The second phase focuses on streamlining Chemistry, Manufacturing and Controls review during product application submissions. Pre-submission meetings and early feedback are intended to ensure continuity between the facility information previously shared and the eventual application dossier.

While PreCheck does not guarantee faster approvals, it aims to reduce the likelihood of significant deficiencies emerging late in the review or inspection process, where remediation is often expensive and time-consuming.

Why FDA PreCheck Matters for Facility Design and Construction

Historically, pharmaceutical facility projects have followed a linear pathway: design, build, qualify, then hope the facility meets regulatory expectations at inspection. PreCheck introduces a more collaborative model, where regulatory expectations can be explored and clarified before concrete is poured or equipment is even purchased.

For complex facilities such as sterile manufacturing, biologics, or radiopharmaceutical production, early regulatory insight can influence:

• Cleanroom classification strategies and zoning concepts
• Material and personnel flow assumptions
• Utilities design and redundancy expectations
• Quality oversight and operational readiness models

By integrating regulatory thinking earlier, organisations may be better positioned to deliver facilities that are inspection-ready on day one.

Implications for Australian and Export-Focused Manufacturers

Although PreCheck is primarily targeted at United States-based facilities, it has important implications for Australian manufacturers, particularly those pursuing export or onshoring strategies.

US Onshoring and Dual-Site Strategies

Australian organisations considering establishing or partnering in United States manufacturing sites may be able to leverage PreCheck as part of a broader onshoring strategy. Early FDA engagement can provide greater confidence to boards and investors that facilities are being designed in alignment with regulatory expectations, potentially reducing risk profiles for major capital investments.

For companies operating dual-site models, lessons learned through PreCheck engagement can also be fed back into Australian facility upgrades, supporting global harmonisation of quality and design standards.

Accelerating Market Entry for Export Products

For Australian manufacturers exporting to the United States, delays at the facility inspection stage can significantly impact commercial timelines. While PreCheck does not replace standard inspection requirements, earlier alignment may help reduce the number and severity of inspection observations, supporting faster progression to approval.

This is particularly relevant for organisations manufacturing critical medicines, sterile injectables, or products subject to heightened regulatory scrutiny.

Strengthening Regulatory and Project Integration

PreCheck also highlights the growing importance of integrating regulatory strategy with capital project delivery. Rather than treating regulatory input as a downstream checkpoint, the programme encourages organisations to embed regulatory intelligence into project governance, design reviews, and risk management activities.

Looking Ahead

Whilst primarily a tool to boost the US manufacturing sector, the FDA PreCheck Initiative encourages proactive regulatory engagement and supply chain resilience which can be no bad thing. For manufacturers planning new facilities or major upgrades, it reinforces the value of engaging regulators early and designing compliance into infrastructure from the outset.

For Australian and export-focused manufacturers, understanding and leveraging programmes such as PreCheck may support more confident investment decisions, smoother approvals, and stronger positioning in global markets, with design lessons learned on US sites being transferrable to others.

As regulatory frameworks continue to evolve, integrating regulatory intelligence into facility design and construction will better place organisations to respond with agility and confidence.

PharmOut Services & Training

Navigating initiatives such as FDA PreCheck requires careful coordination between regulatory, quality, engineering, and construction teams. PharmOut can support clients across this interface by:

• Advising on regulatory strategy during early facility concept and feasibility stages
• Supporting the preparation of facility information suitable for Drug Master File submission
• Reviewing facility designs against United States Good Manufacturing Practice expectations
• Facilitating inspection readiness and quality system maturity assessments
• Aligning Australian and international regulatory requirements for export-focused operations

By supporting early alignment, organisations may be better positioned to take advantage of collaborative regulatory initiatives while maintaining compliance across jurisdictions.

Frequently Asked Questions (FAQ)